---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-013246"
form_type: "8-K"
ticker: "BPTH"
cik: "0001133818"
company_name: "BIO-PATH HOLDINGS, INC."
filed_at: "2024-10-11T23:59:59+00:00"
generated_at: "2026-05-30T15:13:34.066761+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Bio-Path raises ~$4M in private placement; launches obesity drug program BP1001-A

## Summary
- Gross proceeds of ~$4.0M from private placement of pre-funded warrants and series A/B warrants at $0.87 per unit; warrants exercisable at $1.00 per share.
- Initiated development of BP1001-A for obesity using DNAbilize technology; IND-enabling testing expected to begin in Q4 2024.
- Completed enrollment of third dosing cohort (60 mg/m2) of Phase 1/1b trial of BP1002 in refractory/relapsed AML patients.
- Cancelled prior June 2024 series A and B warrants (1,809,955 shares each) held by the same investor upon closing of this placement.

## SEC filing metadata
- accession: 0001558370-24-013246
- form_type: 8-K
- ticker: BPTH
- cik: 0001133818
- company_name: BIO-PATH HOLDINGS, INC.
- filed_at: 2024-10-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133818/000155837024013246/0001558370-24-013246-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133818/000155837024013246/bpth-20241008x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-013246
- JSON: https://secwatch.observer/filing/0001558370-24-013246.json
- Plain text: https://secwatch.observer/filing/0001558370-24-013246.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.